Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPFZ.L Regulatory News (PFZ)

  • There is currently no data for PFZ

Form 8.3 - Pfizer, Inc.

13 Nov 2015 17:08

RNS Number : 7470F
BlackRock Group
13 November 2015
 



Ap19

 

 

FORM 8.3

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

1. KEY INFORMATION

 

Name of person dealing (Note 1)

BlackRock, Inc.

Company dealt in

Pfizer, Inc.

Class of relevant security to which the dealings being disclosed relate (Note 2)

US$0.05 common stock

Date of dealing

11 November 2015

 

2. INTERESTS AND SHORT POSITIONS

 

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

Long

Short

Number

(%)

Number

(%)

(1) Relevant securities

393,832,196 (6.38%)

215,280 (0.00%)

(2) Derivatives (other than options)

1,305,392 (0.02%)

10,860 (0.00%)

(3) Options and agreements to purchase/sell

20,000,000 (0.32%)

21,204,300 (0.34%)

Total

415,137,588 (6.72%)

21,430,440 (0.34%)

 

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:

Long

Short

Number

(%)

Number

(%)

(1) Relevant securities

 

(2) Derivatives (other than options)

 

(3) Options and agreements to purchase/sell

Total

Ap20

 

1. DEALINGS (Note 4)

 

(a) Purchases and sales

 

 

 

Purchase/sale

 

Number of relevant securities

 

Price per unit (Note 5)

Purchase

4,434

USD 33.7400

Purchase

32,919

USD 33.7942

Sale

28,952

USD 33.7400

Sale

1,220

USD 33.7500

Sale

29,700

USD 33.7885

Sale

38,300

USD 33.7956

Please note: there was also a Transfer In of 20,477 Shares.

 

(b) Derivatives transactions (other than options transactions)

 

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit

(Note 5)

(c) Options transactions in respect of existing relevant securities

 

 

(i) Writing, selling, purchasing or varying

 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)

 

(ii) Exercising

 

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 5)

 

(d) Other dealings (including transactions in respect of new securities) (Note 4)

 

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

Ap21

 

2. OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any 

relevant securities to which any derivative referred to on this form is referenced. If none, this

should be stated.

 

 

 

None

 

 

 

Is a Supplemental Form 8 attached? (Note 9) YES

 

Date of disclosure

12 November 2015

Contact name

Gareth Slade

Telephone number

+44 20 7743 2536

If a connected EFM, name of offeree/offeror with which connected

If a connected EFM, state nature of connection (Note 10)

 

 

Ap23

 

 

SUPPLEMENTAL FORM 8

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.1 AND RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DETAILS OF OPEN POSITIONS

 

(This form should be attached to Form 8.1(a) & (b)(i), Form 8.1(b)(ii) or Form 8.3, as appropriate)

 

OPEN POSITIONS (Note 1)

 

Product name,

e.g. call option

Written, or purchased

Number of relevant securities to which the option or derivative relates

Exercise price (Note 2)

Type, e.g. American, European etc.

Expiry date

Call Option

Written

268,100

USD 34.5000

American

13/11/2015

Call Option

Written

261,300

USD 34.0000

American

20/11/2015

Call Option

Written

186,000

USD 34.5000

American

20/11/2015

Call Option

Written

3,500

USD 35.0000

American

20/11/2015

Call Option

Written

186,000

USD 34.5000

American

04/12/2015

Call Option

Purchased

20,000,000

USD 34.5000

American

04/12/2015

Call Option

Written

299,400

USD 35.0000

American

11/12/2015

Call Option

Written

20,000,000

USD 37.5000

American

15/01/2016

 

Notes

 

1. Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell must also be given on this form.

 

2. For all prices and other monetary amounts, the currency must be stated.

 

For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ISEGGGQUGUPAGMW
Date   Source Headline
1st Mar 20178:51 amRNSPress Release
27th Feb 201710:45 amRNSPress Release
24th Feb 20172:19 pmRNSPress Release
22nd Feb 20177:00 amRNSCancellation of UK Listing
31st Jan 20172:56 pmRNSFourth Quarter and Full-Year 2016 Results
24th Nov 20153:20 pmRNSForm 8.3 - Pfizer Inc
24th Nov 20153:19 pmRNSForm 8.3 - Pfizer, Inc.
24th Nov 201512:14 pmRNSForm 38.5(b) - Pfizer Inc
24th Nov 201511:49 amRNSForm 8.1a - Pfizer Inc
24th Nov 201511:46 amRNSForm 38.5(a) - Pfizer Inc
24th Nov 201510:41 amRNSRule 38.5 - Pfizer INC
24th Nov 20157:00 amRNSForm 38.5(b) - Pfizer Inc
23rd Nov 20156:11 pmRNSForm 38.5(a) - Pfizer Inc
23rd Nov 20155:58 pmRNSForm 8.1a - Pfizer Inc
23rd Nov 20153:40 pmRNSForm 8.3 - PFIZER INC
23rd Nov 20153:34 pmRNSForm 8.3 - Pfizer Inc Amendment
23rd Nov 20153:31 pmRNSForm 8.3 - Pfizer Inc
23rd Nov 20153:31 pmRNSForm 8.3 - Pfizer Inc
23rd Nov 20153:28 pmRNSForm 8.3 - ALLERGAN PLC
23rd Nov 20153:21 pmRNSForm 8.3 - Pfizer, Inc.
23rd Nov 20152:56 pmRNSForm 8.3 - Pfizer Inc
23rd Nov 20152:39 pmRNSForm 8.3 - Pfizer Inc
23rd Nov 20152:29 pmRNSForm 8.3 - Allergan Plc
23rd Nov 201512:16 pmRNSForm 8.1 - [Pfizer Inc.]
23rd Nov 201512:04 pmRNSForm 38.5a
23rd Nov 201511:57 amRNSForm 38.5b
23rd Nov 201511:55 amRNSForm 38.5b
23rd Nov 201511:55 amRNSForm 8.3 - Pfizer Inc.
23rd Nov 201510:58 amRNSRule 38.5 - Pfizer INC
23rd Nov 201510:58 amRNSRule 38.5 - Pfizer INC
20th Nov 20153:43 pmRNSForm 8.3 - Pfizer Inc.
20th Nov 20153:34 pmRNSForm 8.3 - Pfizer Inc
20th Nov 20153:25 pmRNSForm 8.3 - Allergan plc
20th Nov 20153:21 pmRNSForm 8.3 - PFIZER INC
20th Nov 20153:17 pmRNSForm 8.3 - ALLERGAN PLC
20th Nov 20153:14 pmRNSForm 8.3 - Pfizer Inc
20th Nov 20153:11 pmRNSForm 8.3 - [PFIZER INC]
20th Nov 20153:07 pmRNSForm 8.3 - Pfizer Inc
20th Nov 20152:58 pmRNSForm 8.3 - Allergan plc
20th Nov 20152:57 pmRNSRule 38.5 - Replacement Pfizer INC
20th Nov 20152:52 pmRNSForm 8.3 - Allergan Plc
20th Nov 20152:44 pmRNSForm 8.3 - Pfizer, Inc.
20th Nov 201512:14 pmRNSForm 8.1 - [Pfizer Inc]
20th Nov 201511:57 amRNSForm 38.5b
20th Nov 201511:55 amRNSForm 8.3 - Pfizer Inc.
20th Nov 201511:53 amRNSForm 38.5b
20th Nov 201511:53 amRNSForm 38.5(b) - Pfizer Inc
20th Nov 201511:52 amRNSForm 38.5a
20th Nov 201511:18 amRNSForm 38.5(a) - Pfizer Inc
20th Nov 201510:37 amRNSRule 38.5 - Pfizer INC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.